Neurocrine Biosciences announced a $2.9 billion all-cash deal to acquire Soleno Therapeutics, strengthening its position in rare disease treatments.
The offer values Soleno at $53 per share, representing a 34% premium to its latest closing price and signaling strong strategic intent.
The acquisition marks Neurocrine’s expansion beyond neuroscience into metabolic disorders, diversifying its therapeutic pipeline.
A key asset in the deal is Vykat XR, the first U.S.-approved therapy targeting hyperphagia linked to Prader-Willi syndrome.
This condition causes persistent, intense hunger, often leading to severe obesity and complex physical and behavioral challenges.
Following the announcement, Soleno shares surged sharply in premarket trading before being temporarily halted.
The transaction underscores growing industry focus on high-value niche therapies, particularly in underserved rare disease segments.
Neurocrine aims to leverage the acquisition to accelerate growth while expanding its footprint in specialized, high-impact treatments.
